Half-year report of the liquidity contract – July 2018 (in French)July 17th 2018
VALBIOTIS confirms its deployment in the United-States, to prepare the future commercialization of VALEDIAJune 7th 2018
Annual results 2017April 3rd 2018
2018 financial communication calendarFebruary 23rd 2018
HALF-YEAR REPORT OF THE LIQUIDITY CONTRACT WITH PORTZAMPARC, WITH INCREASED LIQUIDITYJanuary 31st 2018
consolidated results for the first half of 2017September 29th 2017
International pharmaceutical and nutrition expert Dr. Jean Zetlaoui joins VALBIOTIS’ Supervisory BoardSeptember 20th 2017
VALBIOTIS: Pascal SIRVENT appointed Director of Discovery and Preclinical ResearchSeptember 14th 2017
VALBIOTIS opens a new Clinical Investigation Center at the Institut Pasteur in Lille as part of the Phase IIa study on TOTUM-63, the active ingredient of Valedia®September 6th 2017
The opening of this new Clinical Investigation Center at the Institut Pasteur in Lille which follows the opening of the first Biofortis Mérieux NutriSciences Clinical Investigation Center in Nantes in November 2016 will help accelerate the recruitment of volunteers for the Phase IIa clinical study.
RESULTS OF PHASE I/II CLINICAL STUDY ON THE ACTIVE INGREDIENT OF VALEDIA®June 9th 2017
VALBIOTIS INITIAL PUBLIC OFFERING RECORDS HUGE SUCCESSJune 2nd 2017
SEBASTIEN PELTIER, CEO OF VALBIOTIS, PRESENTS HIS VISION OF A DIABETES-FREE WORLD AT L’ÉCHAPPÉE VOLÉEApril 24th 2017
TWO PARTNERSHIP AGREEMENTS TO ASSESS THE EFFECTS OF TOTUM-63, THE ACTIVE INGREDIENT OF VALEDIA®, ON INTESTINAL MICROBIOTAApril 12th 2017
VALBIOTIS has announced the signing of two partnership agreements, one with Biofortis (Merieux NutriSciences), and the other with the Université Catholique de Louvain (Belgium) and Prof. Patrice D. Cani1 (PhD) as part of a program aimed at evaluating the efficacy of TOTUM-63, the active ingredient of Valedia®, on intestinal microbiota.